ACG plans to open a capsule manufacturing plant and R&D center in Aurangabad, India.
ACG, provider of integrated solutions for the pharmaceutical and nutraceutical industries, has signed a memorandum of understanding (MoU) with the government of Maharashtra for investment into a capsule manufacturing plant and R&D center to be set up in Aurangabad.
The plans, which were announced in a Nov. 22, 2021 press release, are for the plant to be the largest in Asia, capable of producing 40 billion capsules per year, serving both Indian and international pharmaceutical and nutraceutical companies. Additionally, the plant will be significantly powered by green, renewable energy, and will use industry 4.0 technologies.
“Our vision to be a future-ready solutions provider to the pharma industry anywhere in the world and our proposed investment of approximately US$100 million (over INR 600 crores) in this state-of-the-art plant is an integral part of ACG’s mission to double our capsule manufacturing capacity to 240 billion capsules a year,” said Karan Singh, managing director, ACG, in the press release. “This plant will play a key role in further cementing India’s position as the global hub of capsule manufacturing and will add to improved access to high quality, safe, and affordable medicines and nutraceuticals globally.”
“We have a long history of operating in Maharashtra and are privileged to sign this MoU with [the] government of Maharashtra for this mega project which, when ready by 2023, will create around 1000 direct and indirect jobs in the region,” added Nitin Desai, senior vice-president, ACG, in the press release.
Source: ACG